DE602004031973D1 - Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren - Google Patents
Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumorenInfo
- Publication number
- DE602004031973D1 DE602004031973D1 DE602004031973T DE602004031973T DE602004031973D1 DE 602004031973 D1 DE602004031973 D1 DE 602004031973D1 DE 602004031973 T DE602004031973 T DE 602004031973T DE 602004031973 T DE602004031973 T DE 602004031973T DE 602004031973 D1 DE602004031973 D1 DE 602004031973D1
- Authority
- DE
- Germany
- Prior art keywords
- resistant tumors
- interferon
- compositions
- recombinant vectors
- interferon resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52852503P | 2003-12-10 | 2003-12-10 | |
PCT/US2004/041307 WO2005058368A1 (en) | 2003-12-10 | 2004-12-10 | Methods and compositions for treatment of interferon-resistant tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004031973D1 true DE602004031973D1 (de) | 2011-05-05 |
Family
ID=34699875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004031973T Active DE602004031973D1 (de) | 2003-12-10 | 2004-12-10 | Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren |
Country Status (17)
Country | Link |
---|---|
US (7) | US7691822B2 (de) |
EP (2) | EP1691844B1 (de) |
JP (2) | JP4801594B2 (de) |
KR (1) | KR101163248B1 (de) |
CN (1) | CN1893981B (de) |
AT (1) | ATE502654T1 (de) |
AU (1) | AU2004298991A1 (de) |
BR (1) | BRPI0417451A (de) |
CA (1) | CA2548100C (de) |
DE (1) | DE602004031973D1 (de) |
ES (1) | ES2363912T3 (de) |
HK (1) | HK1095525A1 (de) |
IL (1) | IL175820A0 (de) |
NO (1) | NO20062385L (de) |
SG (2) | SG133594A1 (de) |
WO (1) | WO2005058368A1 (de) |
ZA (1) | ZA200604640B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US20030170216A1 (en) * | 2001-12-20 | 2003-09-11 | Schering-Plough Corporation | SYN3 compositions and methods |
NZ543970A (en) * | 2003-06-04 | 2008-09-26 | Canji Inc | Methods and compositions for interferon therapy |
BRPI0417451A (pt) | 2003-12-10 | 2007-04-10 | Canji Inc | método de tratar um tumor resistente a interferon |
WO2006065827A2 (en) | 2004-12-13 | 2006-06-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
EP1974044B1 (de) | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase |
WO2007126950A1 (en) * | 2006-03-31 | 2007-11-08 | Schering Corporation | Parenteral low dose type 1 interferons for bladder cancer |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
CN110075113A (zh) | 2008-04-17 | 2019-08-02 | Pds生物科技公司 | 通过阳离子脂质的对映体刺激免疫应答 |
CA2885741C (en) | 2012-09-21 | 2023-10-17 | Frank Bedu-Addo | Vaccine comprising r-dotap |
CA3005251A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US10335461B2 (en) * | 2016-02-15 | 2019-07-02 | Trizell Limited | Interferon therapy |
EP3442588A4 (de) * | 2016-04-14 | 2020-02-19 | Trizell Ltd. | Stabilisierung von virusvektoren |
KR20200096800A (ko) * | 2017-12-05 | 2020-08-13 | 피디에스 바이오테크놀러지 코퍼레이션 | I형 인터페론 유전자를 자극시키기 위한 양이온성 지질을 포함하는 방법 및 조성물 |
CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
US20200222477A1 (en) * | 2019-01-10 | 2020-07-16 | Trizell Ltd. | Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer |
CN115484985A (zh) | 2020-03-19 | 2022-12-16 | 崔泽尔有限公司 | 温度响应病毒储存系统 |
WO2021198777A1 (en) * | 2020-03-30 | 2021-10-07 | Trizell Ltd. | Compositions and methods for treating cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5618711A (en) * | 1986-08-22 | 1997-04-08 | Hoffmann-La Roche Inc. | Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0331635A3 (de) * | 1988-02-29 | 1990-02-28 | The Board of Regents of the University of Texas System | Zubereitungen zur Behandlung von Blasenkrebs. |
US6207454B1 (en) * | 1989-10-16 | 2001-03-27 | Amgen Inc. | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide |
US5120316A (en) * | 1990-09-28 | 1992-06-09 | Akzo N.V. | Urethral catheter and catheterization process |
US5602023A (en) * | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5804566A (en) * | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
JPH10507758A (ja) * | 1994-10-19 | 1998-07-28 | ジェネティック セラピー,インコーポレイテッド | アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療 |
US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
AU6600396A (en) | 1995-07-28 | 1997-02-26 | David E. Kohne | Method for enhancing chemiluminescence |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
PL332856A1 (en) * | 1996-10-18 | 1999-10-25 | Canji | Methods of and compositions for delivery and expression of nucleic acids as needed by interferon |
US6210969B1 (en) * | 1999-04-28 | 2001-04-03 | Coulter International Corp. | Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
US20030170216A1 (en) * | 2001-12-20 | 2003-09-11 | Schering-Plough Corporation | SYN3 compositions and methods |
WO2003073998A2 (en) * | 2002-03-02 | 2003-09-12 | Board Of Regents, The University Of Texas System | Local production and/or delivery of anti-cancer agents by stromal cell precursors |
NZ543970A (en) * | 2003-06-04 | 2008-09-26 | Canji Inc | Methods and compositions for interferon therapy |
KR20060012661A (ko) * | 2003-06-04 | 2006-02-08 | 캔지, 인크. | 인터페론 요법을 위한 방법 및 조성물 |
BRPI0417451A (pt) | 2003-12-10 | 2007-04-10 | Canji Inc | método de tratar um tumor resistente a interferon |
EP1974044B1 (de) * | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase |
-
2004
- 2004-12-10 BR BRPI0417451-8A patent/BRPI0417451A/pt not_active IP Right Cessation
- 2004-12-10 EP EP04813611A patent/EP1691844B1/de active Active
- 2004-12-10 AU AU2004298991A patent/AU2004298991A1/en not_active Abandoned
- 2004-12-10 DE DE602004031973T patent/DE602004031973D1/de active Active
- 2004-12-10 ES ES04813611T patent/ES2363912T3/es active Active
- 2004-12-10 WO PCT/US2004/041307 patent/WO2005058368A1/en active Application Filing
- 2004-12-10 KR KR1020067010818A patent/KR101163248B1/ko active IP Right Grant
- 2004-12-10 EP EP10180208A patent/EP2301584A1/de not_active Withdrawn
- 2004-12-10 US US11/009,689 patent/US7691822B2/en active Active
- 2004-12-10 JP JP2006543988A patent/JP4801594B2/ja not_active Expired - Fee Related
- 2004-12-10 SG SG200704175-9A patent/SG133594A1/en unknown
- 2004-12-10 CN CN2004800371241A patent/CN1893981B/zh active Active
- 2004-12-10 AT AT04813611T patent/ATE502654T1/de not_active IP Right Cessation
- 2004-12-10 SG SG201007186-8A patent/SG166117A1/en unknown
- 2004-12-10 CA CA2548100A patent/CA2548100C/en not_active Expired - Fee Related
-
2006
- 2006-05-22 IL IL175820A patent/IL175820A0/en unknown
- 2006-05-24 NO NO20062385A patent/NO20062385L/no not_active Application Discontinuation
- 2006-06-06 ZA ZA200604640A patent/ZA200604640B/en unknown
-
2007
- 2007-02-16 HK HK07101922.4A patent/HK1095525A1/xx unknown
-
2010
- 2010-02-16 US US12/706,625 patent/US9439977B2/en active Active
-
2011
- 2011-05-02 JP JP2011103283A patent/JP2011148834A/ja active Pending
-
2015
- 2015-10-27 US US14/924,136 patent/US20160045618A1/en not_active Abandoned
-
2018
- 2018-12-10 US US16/214,180 patent/US20190374654A1/en not_active Abandoned
-
2020
- 2020-01-10 US US16/739,245 patent/US20200164091A1/en not_active Abandoned
-
2021
- 2021-04-29 US US17/244,835 patent/US20210322572A1/en active Pending
-
2023
- 2023-09-15 US US18/368,641 patent/US20240000968A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE502654T1 (de) | 2011-04-15 |
ES2363912T3 (es) | 2011-08-19 |
JP4801594B2 (ja) | 2011-10-26 |
ZA200604640B (en) | 2007-04-25 |
KR20060127397A (ko) | 2006-12-12 |
US20240000968A1 (en) | 2024-01-04 |
WO2005058368A1 (en) | 2005-06-30 |
EP1691844A4 (de) | 2007-11-28 |
US20160045618A1 (en) | 2016-02-18 |
AU2004298991A1 (en) | 2005-06-30 |
SG166117A1 (en) | 2010-11-29 |
US20100266547A1 (en) | 2010-10-21 |
US9439977B2 (en) | 2016-09-13 |
CA2548100C (en) | 2015-03-24 |
HK1095525A1 (en) | 2007-05-11 |
EP2301584A1 (de) | 2011-03-30 |
JP2007513963A (ja) | 2007-05-31 |
JP2011148834A (ja) | 2011-08-04 |
US20210322572A1 (en) | 2021-10-21 |
EP1691844B1 (de) | 2011-03-23 |
CA2548100A1 (en) | 2005-06-30 |
BRPI0417451A (pt) | 2007-04-10 |
KR101163248B1 (ko) | 2012-07-05 |
SG133594A1 (en) | 2007-07-30 |
NO20062385L (no) | 2006-09-05 |
EP1691844A1 (de) | 2006-08-23 |
CN1893981A (zh) | 2007-01-10 |
US20050287119A1 (en) | 2005-12-29 |
CN1893981B (zh) | 2011-03-23 |
US20200164091A1 (en) | 2020-05-28 |
IL175820A0 (en) | 2006-10-05 |
US7691822B2 (en) | 2010-04-06 |
US20190374654A1 (en) | 2019-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004031973D1 (de) | Verfahren und zusammensetzungen zur behandlung von interferon-resistenten tumoren | |
DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
HK1080517A1 (en) | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use | |
DE69434594D1 (de) | Rekombinante adenoviren-vektor und verfahren zur verwendung | |
DE602005019144D1 (de) | Verfahren zur schmerzbehandlung in knochenkrebs du | |
DE60335552D1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
ATE530560T1 (de) | Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten | |
DE602004026867D1 (de) | Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer | |
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
DE60237635D1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
ATE453405T1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs | |
DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
DE602004032345D1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
DE602004015142D1 (de) | Antiangiogene peptide zur behandlung oder vorbeugung von endometriose | |
ATE494301T1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
MXPA05011830A (es) | Peptidos para uso en el tratamiento de la obesidad. | |
DE60208534D1 (de) | Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle | |
DE602004028239D1 (de) | Protease, für die protease codierende dna und verfahren zur herstellung der protease | |
ATE455553T1 (de) | Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung | |
ATE345352T1 (de) | Zusammensetzung einer parvovirus vp1- proteinvariante und eines arvovirus ns1-proteins zur induktion von zytolyse | |
DE60334400D1 (de) | Neue polynukleotid- und polypeptidsequenzen und deren verwendungen | |
DK2186898T3 (da) | Blomstrings-induktion | |
ATE423200T1 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
ATE529437T1 (de) | Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase |